Sutro Biopharma (NASDAQ:STRO) Price Target Raised to $41.00

Sutro Biopharma (NASDAQ:STRO) had its price target upped by Citizens Jmp from $35.00 to $41.00 in a research report released on Thursday,Benzinga reports. They currently have a market outperform rating on the stock.

STRO has been the topic of several other reports. HC Wainwright upgraded shares of Sutro Biopharma from a “neutral” rating to a “buy” rating and upped their price target for the company from $10.00 to $28.00 in a report on Tuesday, March 24th. Wells Fargo & Company raised shares of Sutro Biopharma from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $8.00 to $27.00 in a research note on Tuesday, March 24th. Wall Street Zen upgraded Sutro Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Leerink Partners assumed coverage on Sutro Biopharma in a research note on Tuesday, April 7th. They set an “outperform” rating and a $38.00 target price on the stock. Finally, Citigroup reiterated an “outperform” rating on shares of Sutro Biopharma in a report on Friday, April 17th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $39.63.

Sutro Biopharma Stock Down 4.3%

STRO stock opened at $33.33 on Thursday. Sutro Biopharma has a twelve month low of $6.74 and a twelve month high of $36.00. The stock has a market capitalization of $552.28 million, a price-to-earnings ratio of -1.28 and a beta of 1.31. The firm’s fifty day simple moving average is $24.32 and its two-hundred day simple moving average is $15.71.

Institutional Trading of Sutro Biopharma

Institutional investors and hedge funds have recently made changes to their positions in the company. State of Tennessee Department of Treasury purchased a new stake in Sutro Biopharma in the fourth quarter worth about $86,000. Jane Street Group LLC purchased a new position in Sutro Biopharma during the 4th quarter valued at about $265,000. Bridgeway Capital Management LLC increased its position in Sutro Biopharma by 232.6% during the 3rd quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company’s stock valued at $37,000 after purchasing an additional 30,000 shares during the period. ADAR1 Capital Management LLC bought a new stake in shares of Sutro Biopharma in the 4th quarter valued at about $776,000. Finally, Spruce Street Capital LP purchased a new stake in shares of Sutro Biopharma in the 4th quarter worth approximately $875,000. 96.99% of the stock is currently owned by institutional investors.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.